Just days before Pfizer and Medivation disclosed their merger plans on Aug. 22, 2016, Panuwat allegedly bought short-term, out-of-the-money stock options in Incyte Corporation, which was comparable in size to Medivation and had a similar cancer bent, the SEC said in a complaint.